Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 11/01/22
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International ConferenceGlobeNewsWire • 10/26/22
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022GlobeNewsWire • 09/30/22
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare ConferenceGlobeNewsWire • 09/22/22
Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 08/15/22
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast CancerGlobeNewsWire • 08/01/22
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022GlobeNewsWire • 07/08/22
Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer SettingBenzinga • 06/29/22
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast CancerGlobeNewsWire • 06/29/22
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast CancerGlobeNewsWire • 05/19/22
Aileron Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/17/22
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual GlobeNewsWire • 05/10/22
Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 05/05/22
Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 04/21/22
Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical OperationsGlobeNewsWire • 04/21/22
Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 04/05/22
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/28/22
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth ConferenceGlobeNewsWire • 03/22/22
Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key MilestonesGlobeNewsWire • 01/05/22